Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid vs Lyophilized Palivizumab Immunogenicity in High-Risk Children
NCT00233064Phase 4Completed
- Sponsor
- MedImmune
- Start
- Oct 2005
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of palivizumab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Started Oct 2005; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00233064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233064.